Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NorAD: Guanfacine Add-on in Alzheimer's Disease
NCT03116126Phase 3Active, not recruiting
- Sponsor
- Imperial College London
- Start
- Jan 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Guanfacine with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive subscale at 12 weeks. Started Jan 2019; status: active, not recruiting.
02
Drugs
guanfacine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03116126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116126.